To take care of relapsed or refractory mantle mobile lymphoma in adults which have had at least two traces of systemic therapy, together with a BTK inhibitorThe FDA publishes a notice in the petitions under FDA evaluation in the general public Federal Register. The FDA evaluates the petition, along with other readily available knowledge and informa